title: Superiority of ceftriaxon to cefazolin in a rat model of obstructive jaundice: an experimental study.
abstract: OBJECTIVE
  The objective of this study was to evaluate the serum and bile concentrations of cefazolin and ceftriaxone at the third and sixth hours in an experimental obstructive jaundice model and to identify the rate of excretion of these antibiotics into the bile.
  
  
  METHODS
  Thirty-two Wistar albino rats were used in this study. The bile and serum levels of cefazolin were measured at the third hour in the A1 group and at the sixth hour in the A2 group, with cefazolin administered as 5 mg/rat; while the bile and serum levels of ceftriaxone were studied at the third hour in the B1 group and at the sixth hour in the B2 group, with ceftriaxone administered as 5 mg/rat.
  
  
  RESULTS
  After 3 hr of cefazolin administration, the serum concentration in the A1 group reached a mean of 1.8 μg/ml, while the bile concentration was 90% of the serum concentration, with a mean of 1.6 μg/ml; whereas in the B1 group, the third-hour serum concentration of ceftriaxone was 18.6 μg/ml, while the bile concentration was found to be as high as 330% of this level, i.e., 56 μg/ml. The serum value of cefazolin decreased to 1.4 μg/ml in the A2 group and ceftriaxone decreased to 3.7 μg/ml in the B2 group at the sixth hour.
  
  
  CONCLUSIONS
  Although the excretory level of cefazolin and ceftriaxone into the bile reaches therapeutic doses, the duration for which these levels are above those required for bactericidal activity is short. Ceftriaxone is better concentrated in the serum and bile than cefazolin.
authors.affiliation: Department of Gastroenterological Surgery, Kartal Kosuyolu Yuksek İhtisas Training and Research Hospital, Istanbul, Turkey. enreyhan@yahoo.com
authors.forename: Enver
authors.initials: E
authors.lastname: Reyhan
authors.forename: Mustafa
authors.initials: M
authors.lastname: Duman
authors.forename: Yeliz
authors.initials: Y
authors.lastname: Demirci
authors.forename: Ali Emre
authors.initials: AE
authors.lastname: Atici
authors.forename: Mahmut
authors.initials: M
authors.lastname: Ozer
authors.forename: Burcu
authors.initials: B
authors.lastname: Cevreli
authors.forename: Feza
authors.initials: F
authors.lastname: Ekiz
authors.forename: Tahsin
authors.initials: T
authors.lastname: Dalgic
authors.forename: Musa
authors.initials: M
authors.lastname: Akoglu
authors.forename: Ece
authors.initials: E
authors.lastname: Genc
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D018988:Bacterial Translocation; D001646:Bile / Q000737:chemistry; D002437:Cefazolin / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002443:Ceftriaxone / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002761:Cholangitis / Q000188:drug therapy*; D001651:Cholestasis, Extrahepatic / Q000150:complications*; D004353:Drug Evaluation, Preclinical; D005260:Female; D008026:Ligation; D008297:Male; D008826:Microbial Sensitivity Tests; D051381:Rats; D017208:Rats, Wistar; D044967:Serum / Q000737:chemistry
chemical_list: D000900:Anti-Bacterial Agents; D002443:Ceftriaxone; D002437:Cefazolin